NCT05462717 2026-04-08Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsRevolution Medicines, Inc.Phase 1 Active not recruiting222 enrolled
NCT05983133 2026-04-07A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid TumorsSeagen Inc.Phase 1 Active not recruiting68 enrolled
NCT07213609 2026-03-23A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumorsGlaxoSmithKlinePhase 1/2 Recruiting47 enrolled